Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MaaT 033

Next Previous
Search
Drug Profile

MaaT 033

Alternative Names: MaaT-033

Latest Information Update: 20 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MaaT Pharma
  • Class Antineoplastics; Bacteria
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chemotherapy-induced damage
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Haematological malignancies
  • Phase I Amyotrophic lateral sclerosis
  • No development reported Chemotherapy-induced damage

Most Recent Events

  • 08 Apr 2025 Maat Pharma receives positive outcome of a key DSMB safety interim analysis from the DSMB on ongoing phase IIb PHOEBUS trial in Hematological malignancies
  • 28 Feb 2025 No recent reports of development identified for phase-I development in Chemotherapy-induced-damage in France (PO, Capsule)
  • 21 Jan 2025 Maat Pharma receives positive review from the DSMB on ongoing phase IIb PHOEBUS trial in Hematological malignancies

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top